Disclosures under Regulation 62 of the SEBI LODR
Details of requirements mentioned in sub-regulation 1 of Regulation 62 of Listing Regulation
- Notice of 112th Board Meeting_October 22, 2024_Approval of FS_MaxLife
- Notice of 111th Board Meeting_August 13, 2024_Approval of FS_MaxLife
- Notice of 110th Board Meeting_May 7, 2024_Approval of FS_MaxLife
- Notice for the 109th Statutory Board Meeting_Approval of FS_December 31,2023
- Notice for the 107th Statutory Board Meeting_Approval of FS_September 30, 2023
- Notice for the 106th Statutory Board Meeting_Max Life
- Notice for the 105th Statutory Board Meeting
- Notice for the 104th Statutory Board Meeting_Approval of FS_January 31, 2023
- Notice for the 103rd Statutory Board Meeting_Approval of FS_October 19, 2022
- Notice for the 102nd Statutory Board Meeting_Approval of FS_August 1, 2022
- Notice for the 101st Statutory Board Meeting_Approval of FS_May 10, 2022
- Notice for the 100th Statutory Board Meeting_Approval of FS_January 28, 2022
- Notice for the 99th Statutory Board Meeting_Approval of FS_November 9, 2021
- Notice for the 97th Statutory Board Meeting_Approval of FS_August 10, 2021
- ProceedingsOfEGM_20Nov2024_Reg51(2)_SEBI(LODR)_MaxLife
- DisclosureUnderSEBI LODR_ReceiptOfSCNfromSEBI
- NewspaperPublicationOfFinancialResults_Q2FY25_MaxLife
- SEDisclosure_ChangeInName_SEBILODR_MaxLife
- Outcomes of Board Meeting_Reg51(2)_SEBILODR_October 22 2024_MaxLife
- AuditedFinancialStatements_QE30September2024_MaxLife_SEBILODR
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- DisclosureUnderReg7(1)oftheSEBI(LODR)_QE30September2024_MaxLife
- DisclosureUnderReg6(1)ofSEBI(LODR)_QE30September2024_MaxLife
- HYStatementUnderChapterVIII_NCSOperationalCircular_30September2024
- Compliance Certificate_Reg 3(5) & Reg 3(6) of SEBI (PIT) Regulations_QE30September2024
- StatementOfInvestorGreivances_QE30September2024_MaxLife
- NewspaperPublicationOfFinancialResults_Q1FY25_MaxLife
- IntimationUnderRegulation51_ChangeInSecretarialAuditors_MaxLife
- AuditedFinancialStatements_QE30June2024_MaxLife_SEBILODR
- DisclosureUnderSEBILODR_13082024_MaxLife
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- CertificateOfInterestPaymentUnderReg57_SEBILODR_02Aug2024_MaxLife
- DisclosureUnderPara2OfChapterXIV_NCSoperationalFramework_MaxLife_02Aug2024
- StatementOfInvestorGrievances_MaxLife_QE30June2024
- IntimationUnderReg60(2)ofSEBI(LODR)_RecordDate_InterestPayment_Aug2024
- Compliance Certificate_Reg 3(5) & 3(6) of SEBI (PIT) Regulations_QE30June2024
- DisclosureUnderReg7(1)ofSEBI(LODR)_30June2024_MaxLife
- DisclosureUnderReg6(1)ofSEBI(LODR)_QE30June2024_MaxLife
- NewspaperPublicationOfFinancialResults_Q4FY24_MaxLife
- SubmissionOfAnnualReportFY24_Reg53(2)_SEBILODR_MaxLife
- AuditedFinancialResults_QEandFYE31March2024_MaxLife_SEBI(LODR)
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife_May2024
- Proceedingsof24thAGMofMaxLife_7May2024_Reg51(2)_SEBILODR
- IntimationUnderReg51_ChangeInDirectors_MLIC
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- CertificateUnderReg61(4)ofSEBI(LODR)_MaxLife_31March2024
- ComplianceCertificate_Reg3(5)&Reg3(6)ofSEBI(PIT)Regulations_31Mar2024
- DisclosureUnderChapterXIV_NCSoperationalFramework_SEBI_31Mar2024
- ComplianceCertificateUnderReg7(3)_SEBI(LODR)_31March2024
- DisclosureUnderReg6(1)ofSEBI(LODR)_MaxLife_QE31March2024
- DisclosureUnderReg7(1)ofSEBI(LODR)_MaxLife_31March2024
- IntimationtoNSE_Reg51(2)_SEBI(LODR)_April122024
- StatementOfInvestorGreivances_MaxLife_QE31March2024
- HYstatementUnderChVIIIofNCSOperationalCircular_31March2024
- DisclosureToStockExchange_ApprovalFromCCI_MaxLife
- IntimationToNSE_Para9.1OfChXIOfNCSoperationalcircular_31Mar2024_MaxLife
- DisclosureOnNewsItem_MaxLife
- NewspaperPublicationOfFinancialResults_Q3FY24_MaxLife
- IntimationUnderReg51_ChangeInDirectors_SEBILODR_MLIC
- ProceedigsOfEGM_6February2024_Reg51(2)_SEBI(LODR)_MaxLife
- DisclosureUnderExtantSEBI(LODR)Regulations_IRDAIapprovalOnCapitalinfusion
- AuditedFinancialResults_SEBI(LODR)_QE31December2023_MaxLife
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- StatementOfInvestorGreivances_MaxLife_QE31December2023
- DisclosureUnderReg7(1)oftheSEBI(LODR)_MaxLife_31December2023
- DisclosureUnderReg6(1)ofSEBI(LODR)_MaxLife_QE31December2023
- ComplianceCertificate_Reg3(5)&Reg3(6)ofSEBI(PIT)Regulations_31December2023
- DisclosureToNSE_SEBI(LODR)_ChangeInDirectors_MaxLife_4Dec2023
- DisclosureUnderSEBI(LODR)_MaxLife_CessationOfOfficeOfMrVViswanand
- NewspaperPublicationOfFinancialResults_Q2FY24_MaxLife
- AuditedFinancialResults_SEBI(LODR)_QE30Sept2023_MaxLife
- IntimationTo NSE_Reg50(1)_SEBILODR_MaxLife
- DisclosureUnderReg7(1)oftheSEBI(LODR)_MaxLife_30September2023
- StatementUnderChapterVIII_NCSOperationalCircular_30Sept2023
- CertificateUnder57(5)_SEBILODR2015_MaxLife_QE30September2023
- ComplianceCertificate_Reg3(5)&Reg3(6)ofSEBI(PIT)Regulations_30September2023
- DisclosureUnderReg6ofSEBI(LODR)MaxLife_QE30September2023
- StatementOfInvestorGreivances_MaxLife_QE30September2023
- IntimationToNSE_Reg51(2)_SEBI(LODR)_MaxLife_28Sept2023
- NSEDisclosure_ReappointmentOfMrPrashantTripathy_MLIC
- NewspaperPublicationOfFinancialResults_Q1FY24_MaxLife
- DisclosureUnderSEBILODRRegulations_MaxLife_InfusionOfCapital
- OutcomesOfBoardMeeting_Reg51_SEBILODR_9August2023_MaxLife
- CertificateOfInterestPaymentUnderReg57(1) _02Aug2023_MaxLife
- DisclosureToNSEunderPara2ofChapterXIV_NCSoperationalFramework_MaxLife
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- DisclosureUnderReg7(1)oftheSEBI(LODR)_MaxLife_30June2023
- ComplianceCertificate_Reg 3(5)and 3(6)ofSEBI(PIT)Regulations_30June2023
- DisclosureUnderReg6ofSEBI(LODR)MaxLifeQE_30June2023
- StatementOfInvestorGreivances_MaxLife_30June2023
- IntimationToNSEunderRegulation60(2)OfSEBILODR_MaxLife
- AuditedFinancialResultsAndSecurityCover_March31,2023_MaxLife_NSEDisclosure
- SubmissionOfAnnualReportFY23_Reg 53(2)_SEBILODR_MaxLife
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife
- IntimationToNSEReg51SEBI(LODR)MaxLifeMay122023
- NewspaperPublicationOfFinancialResults_Q4FY23_MaxLife
- DetailsOfIncrementalBorrowings_FY2023_ChapterXIIofSEBINCSoperationalcircular_MLIC
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- CertificateUnderRegulation61OfSEBILODRRegulations
- DisclosureUnderPara2OfChapterXIVOfNCSPperationalFrameworkMLIC
- Initial Disclosure to NSE_LC Under Chapter XII_SEBI Operational Circular_Max Life
- Compliance Certificate Under Clause7(3)ofSEBILODR_MaxLife_YE March 31 2023
- Compliance Certificate_Reg 3(5) & 3(6)of_SEBI(PIT) Regulations_March 31 2023
- DisclosureUnderReg7(1)oftheSEBILODRMaxLifeQEMarch312023
- DisclosureUnderReg6oftheSEBILODRMaxLifeQEMarch312023
- Intmation to NSE_Para 9.1 of Chapter XI of Ncs Operational Circular_March31, 2023
- StatementOfInvestorGrievances_Max Life_March 312023
- StatementUnderSEBINCSOperationCircularMaxLifeMarch312023
- NewspaperpublicationOfQ3FY23ResultsMaxLife
- AuditedFinancialResultsAndSecurityCover_Dec312022_MaxLife_NSEDisclosure
- IntimationToNSE_Reg50_SEBILODR_MaxLife_January232023
- Compliance Certificate_Regulation 3(5) 3(6)_SEBI (PIT) Regulations_December 31 2022
- SubmissionOfRestatedAOAToNSE_January92023
- IntimationToNSE_Reg51(2)_SEBILODR_MaxLife_January2023
- DisclosureUnderReg7oftheSEBILODRMaxLifeQEDecember312022
- DisclosureUnderReg6oftheSEBILODRMaxLifeDecember312022
- StatementOfInvestorGrievances_MaxLife_December312022
- IntimationtoNSE_TransferStakeOfMaxLifeByMSItoMFSL_Nov282022
- DisclosureUnder54(3)_Max Life
- NewspapaerPublicationOfQ2FY23Results_MaxLife
- AuditedFinancialResults_September302022_MaxLife_SEBILODR
- IntimationtoNSE_Reg50_SEBILODR_MaxLife_September2022
- Compliance Certificate_Regulation 3(5), 3(6)_SEBI (PIT) Regulations 2015_18.11.2022
- DisclosureUnderReg6and7oftheSEBILODRMaxLife_QESeptember302022
- StatementOfInvestorGrievances_MaxLife_September302022
- StatementUnderSEBINCSOperationCircularMaxLifeSeptember302022_Revised
- CertificateUnder57(5)_SEBILODR2015_MaxLife_Revised
- IntimationtoNSE_PressReleaseRegardingReceiptOfCOBbyMLPFM_MaxLife
- NewspaperPublicationOfQ1FY23Results_MaxLife
- CertificateOfInterestPaymentUnderReg57(1)_SEBILODR_MaxLife
- QuarterlyAuditedFinancialResults_QE30June2022_MaxLife
- SubmissionToNSE_Para2_ChapterXIVofNCSoperationalframework_MaxLife
- IntimationToNSE_Reg50_SEBILODR_MaxLife_June2022
- DisclosureUnderReg6and7oftheSEBILODRMaxLife_QE_june30_2022
- StatementOfInvestorGrievances_MaxLife_June302022
- IntimationtoNSEunderRegulation60(2)ofSEBILODR_MaxLife
- IntimationtoNSEunderRegulation57(4)OfSEBILODR_MaxLife
- NewspaperPublicationOfQ4AndFY22Results_MaxLife
- AssetCoverUnder54_MaxLife
- AuditedFinancialResults_March312022_MaxLife_SEBILODR
- AnnualReport_Reg53(2)_SEBILODR_MaxLife_10May2022
- IntimationToNSE_Reg51(2)_SEBILODR_MaxLife_May2022
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife_May2022
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife_May2022
- Initial Disclosure to NSE_LC_SEBI circular dated Nov 26, 2018
- Compliance Certificate Under Clause7(3)ofSEBILODR_MaxLife
- Disclosure Under Reg6and7 of the SEBILODR_MaxLife
- StatementOfInvestorGrievances_Max Life_March312022
- StatementUnderSEBINCSOperationCircularMaxLifeMarch312022
- IntimationtoNSEForResignationofDyChiefFinancialOfficerMaxLife
- Intimation to NSE_Para 9.1 of Chapter XI of NCS operational framework_Ma
- IntimationForIncorporationOfWhollyOwnedSubsdiary
- Intimation To NSE_Reg50 SEBI LODR MaxLife January 28-01-2022
- Quarterly Financial Results December-31-2021 MaxLife
- Newspaper Publication Of Q3 FY22 Results MaxLife
- Intimation to NSE Regarding Reg6and7 of SEBI LODR MaxLife December-2021
- Statement of Investor Grievances MaxLife December 31 2021
- Certificate on Asset Coverage Ratio_September 30, 2021
- Intimation to NSE_Reg 6 and 7_SEBI LODR_MaxLife
- Intimation to NSE_Reg50_SEBI LODR_MaxLife_Nov 2, 2021
- Newspaper publication of Q2FY22 Results_MaxLife
- Statement for Utilisation of Proceeds_MaxLife_Sept 30, 2021
- Statement of Investor grievances_MaxLife_Sept 30, 2021
- Statement under SEBI circular dated August 10, 2021
Subordinated Debt Rating
Credit rating of subordinated debt reflects the degree of safety regarding timely servicing of financial obligations.
Rating Agency | Rating | Rating Date |
CRISIL | CRISIL AA+ / Stable | JUN-24 |
ICRA | ICRA AA+ / Stable | JUN-24 |
CRISIL | CRISIL AA+ / Stable | JUL-23 |
ICRA | ICRA AA+ / Stable | JUL-23 |
CRISIL | CRISIL AA+ / Stable | JUL-22 |
ICRA | ICRA AA+ / Stable | JUL-22 |
CRISIL | CRISIL AA+ / Stable | JUL-21 |
ICRA | ICRA AA+ / Stable | JUL-21 |
For investor grievances, please contact:
Anurag Chauhan
Company Secretary and Compliance Officer
Email: investorgrievance@maxlifeinsurance.com
Telephone: +91 124 412 1500
IDBI Trusteeship Services Limited
Address: Asian Building, Ground Floor,
17 R. Kamani Marg, Ballard Estate
Mumbai- 400 001
Phone: 022 40807000
Email: itsl@idbitrustee.com
Website: www.idbitrustee.com